Status:
COMPLETED
A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease
Lead Sponsor:
Takeda
Conditions:
Short Bowel Syndrome
Eligibility:
All Genders
1+ years
Brief Summary
The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revesti...
Eligibility Criteria
Inclusion
- Adult participants (greater than or equal to \[\>=\] 18 years) or pediatric (\>= 1 year and less than \[\<\] 18) with a diagnosis of SBS who are dependent on parenteral support.
- Have received at least one dose of teduglutide according to approved indications.
- Signed the mandatory consent that has been agreed with national regulatory authorities (ANMAT) as applicable.
Exclusion
- \- Not Applicable.
Key Trial Info
Start Date :
November 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04877431
Start Date
November 5 2020
End Date
June 5 2023
Last Update
July 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IC Projects
Buenos Aires, Argentina, C1055AAD